Chardan Capital Weighs in on Kodiak Sciences FY2025 Earnings

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Chardan Capital cut their FY2025 earnings per share estimates for Kodiak Sciences in a report issued on Monday, November 17th. Chardan Capital analyst D. Gataulin now forecasts that the company will post earnings of ($4.41) per share for the year, down from their prior forecast of ($4.25). Chardan Capital currently has a "Neutral" rating and a $14.00 price target on the stock. The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. Chardan Capital also issued estimates for Kodiak Sciences' FY2026 earnings at ($3.30) EPS.

KOD has been the subject of several other research reports. Lifesci Capital started coverage on shares of Kodiak Sciences in a research note on Thursday, October 23rd. They issued an "outperform" rating and a $40.00 price objective for the company. Wall Street Zen cut shares of Kodiak Sciences from a "hold" rating to a "sell" rating in a report on Saturday, October 11th. Weiss Ratings reissued a "sell (e+)" rating on shares of Kodiak Sciences in a research note on Wednesday, October 8th. Jefferies Financial Group began coverage on Kodiak Sciences in a report on Monday, September 22nd. They issued a "buy" rating and a $15.00 price target on the stock. Finally, HC Wainwright raised their price objective on Kodiak Sciences from $24.00 to $26.00 and gave the company a "buy" rating in a research note on Monday. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $22.67.

Read Our Latest Analysis on KOD

Kodiak Sciences Stock Up 1.6%

NASDAQ:KOD opened at $19.53 on Thursday. The firm's fifty day simple moving average is $15.73 and its 200-day simple moving average is $9.31. The stock has a market cap of $1.04 billion, a PE ratio of -4.74 and a beta of 2.88. Kodiak Sciences has a fifty-two week low of $1.92 and a fifty-two week high of $22.14.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.09).

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of KOD. Acadian Asset Management LLC raised its stake in Kodiak Sciences by 27.0% in the 1st quarter. Acadian Asset Management LLC now owns 1,946,134 shares of the company's stock valued at $5,454,000 after purchasing an additional 413,821 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in shares of Kodiak Sciences by 90.1% during the first quarter. Jacobs Levy Equity Management Inc. now owns 685,198 shares of the company's stock worth $1,922,000 after buying an additional 324,722 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Kodiak Sciences during the first quarter worth about $392,000. Adage Capital Partners GP L.L.C. raised its position in shares of Kodiak Sciences by 16.3% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,325,707 shares of the company's stock valued at $3,719,000 after buying an additional 186,180 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its stake in shares of Kodiak Sciences by 163.6% during the first quarter. GSA Capital Partners LLP now owns 205,833 shares of the company's stock valued at $577,000 after buying an additional 127,748 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

Read More

• Five stocks we like better than Kodiak Sciences
• The 3 Best Blue-Chip Stocks to Buy Now
• onsemi Places a $6 Billion Bet on Its Own Stock
• How to Short Nasdaq: An Easy-to-Follow Guide
• HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
• There Are Different Types of Stock To Invest In
• End the Year Strong With These 3 Comeback Champions

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Kodiak Sciences Right Now?

Before you consider Kodiak Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.

While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here